Literature DB >> 23790597

Recent developments in understanding epidemiology and risk determinants of atrial fibrillation as a cause of stroke.

Yousif Ahmad1, Gregory Y H Lip, Deirdre A Lane.   

Abstract

The prevalence of atrial fibrillation (AF) is increasing because of the aging population and advances in the treatment of acute cardiac conditions. It is now approaching epidemic proportions and is associated with significant clinical and public health consequences. Risk factors for the development of AF are numerous and varied and highlight potential treatment measures that could help prevent the occurrence of AF. The emergence of novel risk factors might allow us to increase our understanding of the pathophysiology of the condition and develop novel therapeutic targets. Stroke is the most devastating consequence of AF, and can be prevented with effective oral anticoagulation in patients at increased stroke risk. Our understanding of stroke risk has advanced; we know that the risk is not homogenous and also that only the very lowest risk patients do not benefit from anticoagulation. Clinicians should target their efforts on identifying this "truly low-risk" patient cohort and consider offering formal anticoagulation to all other AF patients. The purpose of this review is to consider the traditional and emerging risk factors for the development of AF itself, and the risk factors for stroke in AF patients and how knowledge of these risk factors can affect clinical practice.
Copyright © 2013 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23790597     DOI: 10.1016/j.cjca.2013.03.009

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  11 in total

1.  Genetic predisposition of stroke: understanding the evolving landscape through meta-analysis.

Authors:  Hai-Dong Huang; Chun-Min Yang; Hai-Feng Shu; Yong-Qin Kuang; Tao Yang; Wei-Qi He; Kai Zhao; Xun Xia; Jing-Min Cheng; Yuan Ma; Jian-Wen Gu
Journal:  Int J Clin Exp Med       Date:  2015-01-15

Review 2.  MicroRNAs and atrial fibrillation: mechanisms and translational potential.

Authors:  Xiaobin Luo; Baofeng Yang; Stanley Nattel
Journal:  Nat Rev Cardiol       Date:  2014-11-25       Impact factor: 32.419

3.  Obesity, metabolic syndrome and risk of atrial fibrillation: a Swedish, prospective cohort study.

Authors:  Petter K Nyström; Axel C Carlsson; Karin Leander; Ulf de Faire; Mai-Lis Hellenius; Bruna Gigante
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

4.  Association between diastolic dysfunction and future atrial fibrillation in the Tromsø Study from 1994 to 2010.

Authors:  Sweta Tiwari; Henrik Schirmer; Bjarne K Jacobsen; Laila A Hopstock; Audhild Nyrnes; Geir Heggelund; Inger Njølstad; Ellisiv B Mathiesen; Maja-Lisa Løchen
Journal:  Heart       Date:  2015-05-13       Impact factor: 5.994

5.  Atrial Fibrillation Progression Is Associated with Cell Senescence Burden as Determined by p53 and p16 Expression.

Authors:  Laurence Jesel; Malak Abbas; Sin-Hee Park; Kensuke Matsushita; Michel Kindo; Hira Hasan; Cyril Auger; Chisato Sato; Patrick Ohlmann; Jean-Philippe Mazzucotelli; Florence Toti; Gilles Kauffenstein; Valérie Schini-Kerth; Olivier Morel
Journal:  J Clin Med       Date:  2019-12-23       Impact factor: 4.241

Review 6.  Atrial fibrillation in the Indigenous populations of Australia, Canada, New Zealand, and the United States: a systematic scoping review.

Authors:  Judith M Katzenellenbogen; John A Woods; Tiew-Hwa Katherine Teng; Sandra C Thompson
Journal:  BMC Cardiovasc Disord       Date:  2015-08-13       Impact factor: 2.298

7.  Predictors and long-term clinical outcomes of newly developed atrial fibrillation in patients with cardiac implantable electronic devices.

Authors:  Bum Sung Kim; Kwang Jin Chun; Jin Kyung Hwang; Seung-Jung Park; Kyoung-Min Park; June Soo Kim; Young Keun On
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

8.  CHA2DS2-VASc score, left atrial size and atrial fibrillation as stroke risk factors in the Tromsø Study.

Authors:  Sweta Tiwari; Maja-Lisa Løchen; Bjarne K Jacobsen; Laila A Hopstock; Audhild Nyrnes; Inger Njølstad; Ellisiv B Mathiesen; Henrik Schirmer
Journal:  Open Heart       Date:  2016-09-06

9.  Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation.

Authors:  Brent A Williams; Michael A Evans; Ashley M Honushefsky; Peter B Berger
Journal:  J Am Heart Assoc       Date:  2017-10-12       Impact factor: 5.501

10.  Trends in Atrial Fibrillation Incidence Rates Within an Integrated Health Care Delivery System, 2006 to 2018.

Authors:  Brent A Williams; Alanna M Chamberlain; James C Blankenship; Elaine M Hylek; Stephen Voyce
Journal:  JAMA Netw Open       Date:  2020-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.